Name: ONCOLYTICS BIOTECH INC (ONCY) Stock
Brand: ONCOLYTICS BIOTECH INC
Rating: 3.5 (3 reviews)

ONCY Latest News, Press Relases and Analysis

All

Press Releases

3 days ago - By: Oncolytics Biotech Inc.

Oncolytics Biotech® Provides Update on Special Meeting of Shareholders

4 days ago - By: Zacks Investment Research

All You Need to Know About Oncolytics Biotech (ONCY) Rating Upgrade to Buy

4 days ago - By: FN Media Group LLC - Mentions: ALXO ERAS IMRX PRLD

Targeted Cancer Therapies Gain Momentum as Precision Market Surges Past $106B

4 days ago - By: Oncolytics Biotech Inc.

Oncolytics Biotech® Aligns with FDA on Pivotal Study Design for Pelareorep in First-Line Pancreatic Cancer

19 days ago - By: Oncolytics Biotech® Inc.

Oncolytics Biotech® Establishes Gastrointestinal Tumor Scientific Advisory Board to Advance Pelareorep as a Platform Immunotherapy

26 days ago - By: Oncolytics Biotech® Inc.

Oncolytics Biotech® Reports Updated Anal Cancer Data Showing Objective Response Rate More Than Double the Current Standard of Care

a month ago - By: Oncolytics Biotech® Inc.

Oncolytics Biotech® Files Circular/Prospectus for Special Meeting of Shareholders To Change Jurisdiction of Incorporation to Nevada

a month ago - By: Benzinga - Mentions: IVA ARAY KIDS VNRX ...

12 Health Care Stocks Moving In Friday's Pre-Market Session

2 months ago - By: Oncolytics Biotech® Inc.

Oncolytics Biotech® Announces Update for Potential First-Line Pancreatic Cancer Registration Study

2 months ago - By: Oncolytics Biotech® Inc.

Oncolytics Biotech® Provides Update on GOBLET Study Progress and U.S. Site Expansion

2 months ago - By: Benzinga - Mentions: AHG COCP CHEK HSDT ...

12 Health Care Stocks Moving In Monday's Pre-Market Session

3 months ago - By: Oncolytics Biotech® Inc.

Oncolytics Biotech® Highlights Strong Efficacy and Translational Data in Metastatic Colorectal Cancer; Will Advance Regulatory Pathway Discussions

3 months ago - By: Oncolytics Biotech® Inc.

Oncolytics Biotech® Provides Updated Clinical Safety Data for Pelareorep, Including Across Multiple Gastrointestinal Tumors

3 months ago - By: Oncolytics Biotech® Inc.

Oncolytics Biotech® Announces Upcoming Investor Conferences in September

3 months ago - By: Oncolytics Biotech® Inc.

Oncolytics Biotech® Announces Voting Results from the Annual General Meeting of Shareholders

4 months ago - By: Oncolytics Biotech® Inc.

Oncolytics Biotech® Reports Second Quarter Financial Results and Details Clinical Program Plans for Pelareorep

4 months ago - By: Oncolytics Biotech® Inc.

ONCOLYTICS BIOTECH INC (ONCY) Stock News

ONCY Latest News, Press Relases and Analysis

Oncolytics Biotech® Provides Update on Special Meeting of Shareholders

All You Need to Know About Oncolytics Biotech (ONCY) Rating Upgrade to Buy

Targeted Cancer Therapies Gain Momentum as Precision Market Surges Past $106B

Oncolytics Biotech® Aligns with FDA on Pivotal Study Design for Pelareorep in First-Line Pancreatic Cancer

Oncolytics Biotech® Establishes Gastrointestinal Tumor Scientific Advisory Board to Advance Pelareorep as a Platform Immunotherapy

Oncolytics Biotech® Reports Updated Anal Cancer Data Showing Objective Response Rate More Than Double the Current Standard of Care

Oncolytics Biotech® Files Circular/Prospectus for Special Meeting of Shareholders To Change Jurisdiction of Incorporation to Nevada

12 Health Care Stocks Moving In Friday's Pre-Market Session

Oncolytics Biotech® Announces Update for Potential First-Line Pancreatic Cancer Registration Study

Oncolytics Biotech® Provides Update on GOBLET Study Progress and U.S. Site Expansion

12 Health Care Stocks Moving In Monday's Pre-Market Session

Oncolytics Biotech® Highlights Strong Efficacy and Translational Data in Metastatic Colorectal Cancer; Will Advance Regulatory Pathway Discussions

Oncolytics Biotech® Provides Updated Clinical Safety Data for Pelareorep, Including Across Multiple Gastrointestinal Tumors

Oncolytics Biotech® Announces Upcoming Investor Conferences in September

Oncolytics Biotech® Announces Voting Results from the Annual General Meeting of Shareholders

Oncolytics Biotech® Reports Second Quarter Financial Results and Details Clinical Program Plans for Pelareorep

Oncolytics Biotech® Announces Voluntary Delisting from the Toronto Stock Exchange